

# Matthew N Meriggioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1085777/publications.pdf>

Version: 2024-02-01

9  
papers

1,071  
citations

1307594

7  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. <i>Lancet Neurology</i> , The, 2009, 8, 475-490.	10.2	775
2	Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 5296-5306.	0.8	72
3	Myasthenia Gravis: Diagnosis. <i>Seminars in Neurology</i> , 2004, 24, 31-39.	1.4	64
4	Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. <i>Neurotherapeutics</i> , 2016, 13, 118-131.	4.4	53
5	Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. <i>Journal of Autoimmunity</i> , 2014, 52, 64-73.	6.5	45
6	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. <i>Journal of Neuromuscular Diseases</i> , 2017, 4, 169-173.	2.6	33
7	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	2.2	24
8	TDP $\epsilon$ 43 Proteinopathy: Aggregation and Propagation in the Pathogenesis of Amyotrophic Lateral Sclerosis. <i>Movement Disorders</i> , 2016, 31, 1139-1139.	3.9	4
9	The Clinical Spectrum of Necrotizing Autoimmune Myopathy. <i>JAMA Neurology</i> , 2015, 72, 977.	9.0	1